Table 3.
Direct medical costs (base case analysis)
| Including hHF impact | Excluding hHF impact | ||
|---|---|---|---|
| Empagliflozin + metformin | Empagliflozin + metformin | Oral semaglutide + metformin | |
| Total cost (GBP) | 28,193 | 28,280 | 34,441 |
| Treatment | 15,979 | 15,888 | 22,192 |
| Management | 731 | 727 | 727 |
| CVD | 6785 | 6954 | 6960 |
| Renal | 873 | 924 | 896 |
| Ulcer/amputation/neuropathy | 945 | 935 | 911 |
| Eye | 2406 | 2381 | 2310 |
| Non-severe hypoglycaemia | 284 | 282 | 264 |
| Severe hypoglycaemia (required non-medical assistance) | 140 | 140 | 135 |
| Severe hypoglycaemia (required medical assistance) | 51 | 50 | 46 |
Costs presented are for empagliflozin or oral semaglutide in addition to metformin as dual therapy
CVD cardiovascular disease, GBP Pound sterling, hHF hospitalisation for heart failure